Globus Medical (GMED)vsStryker Corporation (SYK)
GMED
Globus Medical
$80.00
0.00%
HEALTHCARE · Cap: $10.91B
SYK
Stryker Corporation
$305.66
-1.38%
HEALTHCARE · Cap: $112.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 715% more annual revenue ($25.27B vs $3.10B). GMED leads profitability with a 18.9% profit margin vs 13.2%. SYK appears more attractively valued with a PEG of 1.43. GMED earns a higher WallStSmart Score of 74/100 (B).
GMED
Strong Buy74
out of 100
Grade: B
SYK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.4%
Fair Value
$138.77
Current Price
$80.00
$58.77 discount
Margin of Safety
-35.2%
Fair Value
$223.02
Current Price
$305.66
$82.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 66.7% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 21.3%
Revenue surging 27.0% year-over-year
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMED
The strongest argument for GMED centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 18.9% and operating margin at 21.3%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GMED profiles as a growth stock while SYK is a value play — different risk/reward profiles.
GMED carries more volatility with a beta of 0.95 — expect wider price swings.
GMED is growing revenue faster at 27.0% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
GMED scores higher overall (74/100 vs 59/100), backed by strong 18.9% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?